VYNE Therapeutics Shares Jump On Encouraging Preclinical Data From VYN201 Program In Rheumatoid Arthritis

VYNE Therapeutics Inc VYNE announced positive preclinical data from its VYN201 program in the rheumatoid arthritis (RA) animal model.
The Company will start a first-in-human trial for VYN201 in 2H of 2022.
VYN201 demonstrated marked inhibition of paw thickening at the 1 and 10mg/kg doses. At both doses, the inhibition of paw thickening was statistically significant in the treated paw relative to the untreated rear paw on day 12.
Limbs treated with VYN201 at the 1 and 10mg/kg dose levels had an average arthritis score of 0.57 and 0.67, respectively, or near normal.
Related: VYNE Therapeutics' BET Inhibitor Shows Encouraging Preclinical Action In Skin Disorder.
VYN201 demonstrated improvement in signs and symptoms of joint inflammation, and no treatment effect was observed in untreated limbs, suggesting a locally acting anti-inflammatory effect of VYN201.
In contrast, animals that received systemic dexamethasone experienced a treatment effect in all limbs.
Animals treated with systemic dexamethasone experienced continued weight loss, while all other treatment groups experienced improved body weights following recovery from the RA stimulant.
Price Action: VYNE shares are up 7.04% at $0.73 during the market session on the last check Wednesday.